ANI Pharmaceuticals
ANIP
126 hedge funds and large institutions have $330M invested in ANI Pharmaceuticals in 2022 Q3 according to their latest regulatory filings, with 17 funds opening new positions, 33 increasing their positions, 50 reducing their positions, and 10 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
13% more capital invested
Capital invested by funds: $293M → $330M (+$36.9M)
5% more funds holding
Funds holding: 120 → 126 (+6)
1.61% more ownership
Funds ownership: 57.3% → 58.92% (+1.6%)
34% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 50
58% less call options, than puts
Call options by funds: $726K | Put options by funds: $1.72M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$7M |
| 2 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$6.17M |
| 3 |
Balyasny Asset Management
Chicago,
Illinois
|
+$4.76M |
| 4 |
WCM
Wedge Capital Management
Charlotte,
North Carolina
|
+$4.44M |
| 5 |
GACM
Global Alpha Capital Management
Montreal,
Quebec, Canada
|
+$3.27M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$4.6M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$2.17M |
| 3 |
BlackRock
New York
|
-$1.83M |
| 4 |
Goldman Sachs
New York
|
-$1.48M |
| 5 |
Fuller & Thaler Asset Management
San Mateo,
California
|
-$1.38M |
ANIP Hedge Fund Activity: Q3 2022 in Review
126 of the 5,828 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2022, worth a combined $330M — up 13% from $293M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new ANIP positions and 10 closed out — a net gain of 7 holders — while 33 added to existing stakes and 50 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $7M. The largest seller was Deutsche Bank, cutting an estimated $4.6M.
- 126 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2022, up from 120 in Q2 2022.
- Funds reported $330M of ANI Pharmaceuticals stock for Q3 2022, up 13% quarter-over-quarter.
- 17 funds opened new ANI Pharmaceuticals positions in Q3 2022 and 10 closed out, a net change of +7 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2022 was Rubric Capital Management (New York), an estimated $7M added.
- The largest ANI Pharmaceuticals seller in Q3 2022 was Deutsche Bank, an estimated $4.6M sold.
Based on aggregated 13F filings for Q3 2022.